Background

Antibiotics are a key commodity for global health, and inadequate access is a major contributor to global mortality. COVID-19 has refocused attention on global pharmaceutical value chains and the need for sustainable and secure production and supply of key products, including antibiotics. Production of antibiotics and their active pharmaceutical ingredients is capital- and technology-intensive, however, and value chains are dominated by a limited number of countries. China is known to be one of the largest producers, but its position in global value chains has not previously been analyzed. This is important for discussions about equitable and resilient global supplies, including through global instruments such as the pandemic treaty.

With competitive price and timely delivery, Jiayi Pharmaceutical sincerely hope to be your supplier and partner.

Methods

This study utilizes data from the International Trade Center database to analyze global and Chinese export trade patterns in the antibiotic industry from to , along with trends in comparative advantage. The antibiotic trade data included in this study covers different antibiotic products, including some tuberculosis drugs, while other types of antimicrobial drugs (such as antivirals, antiparasitics) are excluded.

Results

The export share of antibiotic ingredients from China increased from 9.0% in to 44.5% in . China is the largest exporter of antibiotic ingredients (with a strong comparative advantage). Additionally, the export share of antibiotic medicines increased from 0.5% in to 6.5% in , making it the 7th largest exporter of antibiotic medicines (though with a comparative disadvantage). The proportion of antibiotic medicines in China’s exports is gradually increasing, though the country’s antibiotic industry is expected to remain in the upstream-to-midstream segments of the global supply chain in the short term. China’s export market for antibiotic medicines is fragmented, focusing on developing countries, though European (17.9% in ) and North American markets (13.1% in ) are increasing in importance. China’s weight in global antibiotic exports, particularly of antibiotic ingredients, creates dependencies for countries reliant on China, and for Chinese companies reliant on certain overseas markets.

Conclusions

China is central to global antibiotic manufacturing. Policies promoting the reshaping of global supply chains and reshoring of critical medicines will likely create challenges for Chinese exporters, though are unlikely to alter the global supply structure in the short term. This has implications for Chinese policymakers, including strengthening innovation, quality, international competitiveness, and diversifying markets. Equally, China’s huge manufacturing capability, cost advantages, and rapid scientific and technological progress, make the country an inevitable and important part of future arrangements to ensure equitable global antibiotic access. As the Chinese government considers its global health policy in the post-COVID-19 era, antibiotics may provide an area where China can play a distinctive role.

Antibiotics are a group ofmedicines that are key to the functioning of effective health systems, and an essential commodity for global health. Lack of access to antibiotics is estimated to cause more deaths globally than antimicrobial resistance (AMR) [1], primarily in low- and middle-income countries (LMICs) [2]. While the reasons for limited access to antibiotics are complex [2,3,4], reliable supplies are an important element and there is a recognised need for global coordination to ensure this [4].

The COVID-19 pandemic has refocused attention on the importance of complex global value chains in the supply of pharmaceuticals, and the need for sustainable and secure production and supply of key products [5, 6]. The majority of antibiotic medicine supply comes from a small number of countries, including Italy, India, Canada and German [7]. This reflects the fact that antibiotic medicines are a capital - and technology - intensive sub-sector within biopharmaceuticals. In the antibiotic supply chain, the upstream segment primarily involves raw material production, while the downstream segment is focused on antibiotic formulations. Better understanding global patterns of production and distribution of antibiotics is necessary for ensuring sustainable and secure supply and improving access, especially in LMICs. To date, there have been only a limited number of studies of this [8, 9]. We believe this study to be the first to focus on China, one of the most important suppliers of antibiotics and precursors globally.

As the only country to cover all industrial categories in the WHO Industrial Classification, China has become an important link in global supply chains [10], particularly in industries like pharmaceutical manufacturing, automobiles, and electronics [11, 12]. Since joining the WTO, China's pharmaceutical sector has seen rapid growth, with a significant increase in its participation in international division of labor [13]. In the antibiotic sub-sector, data from the International Trade Centre (ITC) indicate that China's production and export volume of antibiotics was ranked number one globally in [11], while around 45% of the active pharmaceutical ingredients (APIs) needed for global antibiotics are sourced from China, as shown later in the paper [14]. Moreover, the significant increase in pharmaceutical exports from China to India and the US [9, 15]. Reports from indicate that India imports nearly 70% of its APIs from China [16]. In -21, China (22%) became the third-largest supplier of APIs to the United States, following India and Italy [17], suggesting an increasing global direct or indirect dependence on supplies from China [18]. Examples of this dependency include a case in when the shutdown of a single factory in China led to a global shortage of the crucial antibiotic piperacillin-tazobactam, and benzathine penicillin, for which only three API manufacturers remain, all of which are in China [19, 20].

China’s antibiotic industry has a long history, though one which sits out the mainstream of antibiotic production and research in developing countries. China’s research into and production of antibiotics (initially mainly penicillin, then streptomycin) started in the late s, with development of an antibiotics industry in the s, with backing for research centres and state-owned facilities from the central government and support from the former Union of Soviet Socialist Republics (USSR). Post- and the founding of the People’s Republic of China, the country was very isolated internationally and not integrated in mainstream global efforts to scale up technology transfer to developing countries in the s [21].

Pharmaceuticals and biotech have become an increasingly important industrial sector for China in the last two to three decades, however, and increasing investment and policy support have sought to transform an industry primarily focused on generics and ‘me too’ drugs into one focused on value and innovation [22,23,24]. China’s antibiotic exports have developed rapidly, as part of an export-oriented pharmaceutical manufacturing strategy, but as with other segments of the market, antibiotic exports are primarily concentrated in APIs and generic drugs [11, 25]. There is recognition of the need for the country’s antibiotic sector to transition toward innovation-driven growth, balancing the country’s traditional role as a fast follower in antibiotics [22].

China has introduced a series of strategic national policies to elevate its position in global value chains. In , the country set the goal of “promoting the country's manufacturing industry to move up the global value chain.” This objective was reiterated in and with an emphasis on “enhancing the autonomy, security, and control of industrial and supply chains” [26]. Regarding antibiotics, China has introduced various policies to encourage and support the R&D of next-generation antibiotics, accelerate their commercialization, and streamline the approval process for new drugs [27]. These measures have, to some extent, promoted competition between domestic and international new drugs in the local market, driving innovation among domestic pharmaceutical companies [28, 29]. The most notable example is the “National Action Plan to Contain Antimicrobial Resistance (-)” [30]. In recent years, Chinese companies have gained international certifications from agencies including Food and Drug Administration (FDA), Certificate of Suitability (COS), the Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA), and Therapeutic Products Directorate (TPD), enabling them to export to high-end global markets and enhancing their international competitiveness [31].

The COVID-19 pandemic has had a profound impact on global supply chains [32]. Before the pandemic, concerns had already been raised about the risks of relying on China’s pharmaceutical supply chains, but these issues gained greater attention and urgency in the wake of the global health crisis. Countries, led by the US, began rethinking the global layout of their manufacturing supply chains [33, 34]. China’s antibiotic industry faces multiple pressures, including the need to strengthen domestic innovation, dependency on trade in comparatively lower-value antibiotic ingredients, and pressures likely to come from the reshaping of global antibiotic ingredient supply chains. Therefore, assessing China’s role in the global antibiotic supply chain, optimizing the pharmaceutical industry landscape, and enhancing international competitiveness have become critical. In this study, we aim to clarify China’s role in the global antibiotic industry chain by analyzing China’s evolving antibiotic trade and exploring the changing trends in the comparative advantage of Chinese-produced antibiotics.

Descriptive analysis of trade

Analyzing China's antibiotic trade trends by the import and export value, the proportion of different products in imports and exports, and the changes in export values to major countries, focusing on the top ten countries with the highest antibiotic exports in .

Global trade network

The trade network is a complex economic system composed of interconnected national or regional economies. Based on the trade data of the top ten countries with the highest antibiotic exports in , trade network analysis is utilized to analyze the global antibiotic industry structure, including trade value and partnerships. Treemaps are a popular tool for visualizing hierarchical data: items are represented by nested rectangles, with the area of each rectangle corresponding to the data for that item. Within the same hierarchy level, larger rectangles indicate a greater proportion of that data within the whole [37, 38]. The treemap is used here to illustrate China's antibiotic export markets and values, highlighting the destinations and scale of China's antibiotic exports.

Comparative advantage: definition and indicators

Comparative advantage refers to a country’s ability to manufacture and export goods and products that are relatively cheaper than similar goods manufactured and exported by other countries and foreign competitors [39]. The Balassa Revealed Comparative Advantage (RCA) index measures a country’s comparative advantage in exporting specific commodities relative to other countries within a free trade framework and is widely used in comparative research [40]. To quantitatively assess the comparative advantage of various antibiotic products among the leading exporting countries, this study uses the comparative advantage index to analyze the antibiotic products of the top ten countries with the highest exports of antibiotic medicines and ingredients in . The formula is as follows:

$${\text{RCA}}_{\text{ij}} = \left({\text{X}}_{\text{ij}}/{\text{X}}_{\text{j}}\right) / \left({\text{X}}_{\text{iw}}/{\text{X}}_{\text{w}}\right)$$

Where, RCAij, Xij, Xj, Xiw and Xw are Balassa’s index of revealed comparative advantage, exports of good i by country j, exports of all goods by country j, exports of good i by all countries in the world and exports of all goods by all countries in the world, respectively [41].

If the value of index is less than 1, the country has a revealed comparative disadvantage (loss) in the trade of good i and conversely, if the ratio is greater than 1, the country has a revealed comparative advantage in the trade of that good; the higher the value, the greater the comparative advantage [42]. The trend of RCAij shows the changes in export share of commodity i to country j [43]. Evaluating the incremental trend of the RCAij over time highlights the improvement in a country’s competitive standing for a given commodity, reflecting the creation or utilization of new opportunities [44].

The Comparative Advantage index has limitations: 1) It is asymmetric: comparative disadvantage ranges from 0 to 1, while advantage spans from 1 to infinity. 2) There is a small-country bias: when Xj is small relative to Xw, RCA tends to be higher, often making smaller countries appear more competitive than larger ones [40, 45, 46]. In the case of China’s export of antibiotics and antibiotic ingredients, the Balassa RCA index allows a robust assessment of comparative advantage.

Value of China’s antibiotic exports

Supplementary table.1 reveals a significant surge in China’s antibiotic exports over the past two decades. In , China’s exports of antibiotic totaled $5.46 billion, compared to $770 million in , with an average annual growth rate of 10.85%. Since , China has consistently been a net exporter of antibiotic ingredients. The trade surplus has steadily risen from $0.47 billion in to $3.86 billion in , reflecting an average annual growth rate of 11.70%. Notably, the COVID-19 pandemic contributed to a surge in the trade surplus, which increased by $0.31 billion compared to . Figure 1 further demonstrates the yearly growth of China’s total antibiotic exports since . It indicates that the most significant growth periods were - and -, with a noticeable spike after the onset of the COVID-19 pandemic. The trend in antibiotic ingredient exports closely aligns with this pattern. Notably, from to , China’s share of the global market for antibiotic exports exhibited an overall upward trend, with the most significant increase observed in the market share for antibiotic ingredients.

Overall, while the export value and global market share of both antibiotic ingredients and antibiotic medicines has been on an upward trend over the past two decades. Nevertheless, China’s antibiotic exports remain focused on ingredients, though as Figure 2 shows, that the proportion of antibiotic ingredients within the total antibiotic exports has been declining. This downward trend has become more pronounced since . To explore the evolution of supply structure and market demand, we also focused on imports. The import of antibiotic medicines has shown an upward trend, with import values beginning to rise rapidly in and again in . As for antibiotic ingredients, imports have steadily increased since , with a spike in . By , the import value had reached $0.69 billion (Fig. 1).

Status and position of China’s global export of antibiotic medicines and ingredients from to

The results show that the leading exporters of antibiotic medicines were Italy, Canada, India, and Germany, while China, Italy, India, and Switzerland were the key exporters of antibiotic ingredients (in appendix). According to statistics, in , China’s antibiotic exports accounted for 18.9% of global antibiotic exports, with antibiotic ingredients making up 44.5% of global antibiotic ingredients exports, making China the largest exporter of antibiotic ingredients worldwide. Notably, China accounts for nearly half of the global export of antibiotic ingredients, but the number of trading partners it has is not significantly different from that of India and other countries, with considerable overlap among them. This indicates that China’s export market for antibiotic ingredients is highly concentrated and faces competition from India. Interestingly, a significant portion of China’s antibiotic ingredient exports goes to India (about 1/3), accounting for 82.7% of India’s import share, though India is seeking to reshore API production in the wake of COVID-19 and linked to concerns over excessive reliance on overseas suppliers for critical health commodities [47]. Moreover, among the top ten exporters of antibiotic ingredients (excluding Spain and Singapore), China is also one of the main export destinations. We discuss this in more detail below.

The analysis of the antibiotic medicines trade network reveals that, aside from the relatively lower export values of the UK, the US and France, the differences in export values among other countries are not significant. The market concentration of countries’ exports of antibiotic medicines differs: exports from China, the UK, France, and Belgium are relatively diversified, indicating a lower market concentration (Fig. 3a), while exports from the remaining countries are mainly directed toward one or a few key destinations, suggesting a higher market concentration.

Want more information on Antibiotics Exporter? Feel free to contact us.

Destinations of antibiotic ingredients and medicines exported from China

Figure 4 shows the geographical distribution of destinations for China’s antibiotic exports. Taking a regional perspective, China’s antibiotic medicine (penicillins, streptomycins and their derivates) export trade is predominantly directed towards West Africa, South America, Southeast Asia, and Eastern Africa. Specifically, West Africa alone accounts for over $45.36 million in exports, representing 17.09% of the total. If the focus is on countries, however, the US is the second-largest single destination for China’s exports of antibiotic medicines (penicillin, streptomycin, and their derivatives). Russia, India, and Germany are also key export destinations. In contrast, the export trade for antibiotic medicines (other antibiotics) is mainly focused on countries in Western Europe, North America, South Asia, Southeast Asia, and South America, with exports to Western Europe and North America exceeding $ 270.34 million. Additionally, exports of antibiotic ingredients span all continents, with the majority still concentrated in South Asia ($ 1.55 billion). Western Europe is another major export destination. The US, Italy, Germany, and France, which are leading countries in medical innovation, account for a significant portion of China’s antibiotic ingredient export value. Notably, regions with limited pharmaceutical manufacturing capacity, such as Africa, also hold a share in China’s export value.

China’s comparative advantage vis-à-vis the world’s largest exporters of antibiotic ingredients and medicines

As depicted in Fig. 5, China’s apparent comparative advantage index in the field of antibiotic medicines has consistently remained below 1, an accepted benchmark for comparative advantage in this sector, whereas Italy and India, a major exporter of antibiotics, has an index exceeding 1.5. Meanwhile, Canada’s index has grown rapidly since , remaining consistently above 2. In terms of market share, since , China’s market share in antibiotic medicines has been continuously expanding, while the global market share in antibiotic medicines has remained relatively stable. These indicate that China’s export of antibiotic medicines is not a comparative advantage, though this has been improving somewhat since , with the index rising from 0.13 in to 0.43 in , though this remains substantially below the 1 that would indicate comparative advantage. In contrast, China enjoys a significant export advantage in the field of antibiotic ingredients, with a comparative advantage index which surpasses 1.5, and which continues to grow. Both China and the world have shown an expanding trend in the market share of antibiotic ingredients, but China’s growth rate is faster than that of the world. Moreover, Italy, India, and Switzerland, also major exporters of antibiotic ingredients, have a comparative advantage index generally consistently above 2, reflecting strong international competitiveness. Furthermore, the gap between China’s relative advantage in antibiotic ingredients and antibiotic medicines is gradually weakening, with the relative index dropping from 18.16 in to 6.90 in . Overall, the data suggests that at present and in the short term, China’s export advantage in antibiotic ingredients is relatively pronounced, and that the country’s comparative disadvantage in export of antibiotic medicines will take some time to be overturned.

China’s export of antibiotic medicines and ingredients

Figures 6 and 7 illustrate the primary export markets for China’s antibiotic ingredients and medicines, as well as the annual trends in their export values. Among the top ten export destinations in , the overall export value for antibiotic medicines has been rising, with a noticeable acceleration after , particularly in the US. The US has now become the main market for China’s export of antibiotic medicines (other antibiotics), whereas the main market for antibiotic medicines (penicillins, streptomycins and their derivates) has shifted from Nigeria and India to Nigeria, Japan, and the US (Fig. 6). Notably, exports of antibiotic medicines (penicillins, streptomycins and their derivates) to the US started to grow in and surged in , while exports to Japan saw rapid growth from , reaching $23.52 million in . India has consistently been the primary destination for China’s export of antibiotic ingredients (Fig. 7). India has always accounted for about a third of China's export share, and the increase in exports to India has outpaced other destinations. According to statistics, antibiotic ingredients imported from China make up 82.7% of India’s total imports of antibiotic ingredients by value.

This study, based on data from the ITC, examines the evolution and characteristics of Chinese antibiotic trade from to . It explores the current state of global and Chinese antibiotic export trade, as well as China’s role and trends in the global antibiotic supply chain. The main findings from this research are as follows.

Trends in China’s antibiotic export trade

China’s export trade of antibiotics is influenced by macroeconomic policies. On the export side, the focus has primarily been on low - value ingredients [48], though the export of antibiotic medicines is expanding. The overall export value has shown an upward trend, driven largely by antibiotic ingredients. This can be attributed to a combination of factors, including market diversification, international environmental protection, demand patterns, and cost advantages [14, 49, 50]. The export of antibiotic ingredients surged after , possibly due to the treatment of secondary infections and overuse during the COVID-19 pandemic [51,52,53]. The fact that, for both antibiotic medicines and antibiotic ingredients, the cumulative growth rate of the export volume is lower than that of the export value indicates a significant increase in the average unit price. This suggests ongoing industrial restructuring, with a gradual shift from lower-value to higher-value products. Additionally, the export value and proportion of antibiotic medicines vis-à-vis ingredients have been expanding since . This may be linked to policies like the Medium- and Long-Term Science and Technology Development Plan (-), issued in [30], aimed at enhancing the quality of medicines. The Major Projects Plan, established in , which prioritizes new drug R&D, may have also played a role [54].

On the import side, there was a significant surge in antibiotic medicines imports in and , with a steady increase in antibiotic ingredient imports starting in , culminating in a sharp spike in . This trend can be explained by various favorable policies, including improved import regulation, reduced import barriers, initiatives to promote generic drug consistency, and supply-side structural reforms in the pharmaceutical sector [55]. Notable policy changes include the revision of the Drug Registration Regulation, the Guideline for the Consistency Evaluation of Generic Drug Quality and Efficacy, the Classification Guidance for Generic Drug Quality and Efficacy Consistency Evaluation, and the National Drug Safety 12th Five-Year Plan [56]. The implementation of drug consistency evaluations has driven demand for high-quality imported ingredients and medicines. Environmental challenges leading to shortages or price spikes for ingredients, coupled with multinational companies’ increasing procurement from overseas, have likely further spurred significant growth in imports [57]. The cumulative growth rate of imports for antibiotic ingredients and medicines is lower than that of import value, indicating an increase in average unit value. This may suggest that China's industrial structure is adjusting, with import demand remaining focused on higher-value products.

Overall, China’s antibiotic industry holds a position in the upstream-to-midstream segment of the global antibiotic supply chain [51,52,53, 58]. The worldwide supply of antibiotic ingredients is, to a substantial extent, dependent on China’s exports. China is now the world’s 7th largest exporter of antibiotic medicines and the largest exporter of antibiotic ingredients. Noticeably, India’s antibiotic ingredients are relatively dispersed [59], whereas China's antibiotic ingredient exports are relatively concentrated in a small number of markets. About 1/3 of those exports go to India, making up 82.7% of India's total imports. As a major exporter of antibiotics, India today is highly dependent on importing antibiotic ingredients from China [9]. Consequently, the antibiotic manufacturing industry in many countries relies, either directly or indirectly, on China, positioning China as a critical player in the global antibiotic supply chain. This phenomenon was illustrated in , when the shutdown of a single factory in China caused a worldwide shortage of the cornerstone antibiotic piperacillin–tazobactam [20, 60].

However, this concentration of export markets heightens the reliance of Chinese exports on specific regions. If there were issues with exports to India, for example, it would be difficult to offset them through stability or counterbalancing in other export markets [50]. Presently, countries are placing more emphasis on reshoring ingredient production, which could pose challenges for China [33, 34]. Some of the most active measures are likely to come from the United States’ Biosecure Act, which will reduce US companies’ ability to do business with certain Chinese companies [61, 62]. Similarly, Indian policies to reshore API production are likely to be significant for China, given the weight of India in Chinese exports [47, 63, 64]. Equally, increasing environmental regulation of antibiotic production may also affect China [65]. It is not yet clear over what timeframe this is likely to alter the global supply structure or the potential size of the impact of measures such as these [50].

Conversely, China’s antibiotic medicine export market is not highly concentrated, with exports going to a large number of countries, indicating that it may be in a growth phase. This dispersion reduces economic risk but increases trade costs, suggesting China may lack competitive high-tech and high-value-added products [50]. Interestingly, China is also a primary export destination for other major antibiotic ingredient exporters, likely due to the domestic demand for high-quality, high-value ingredients. This points to the potential for China to optimize its product structure and focus on precision and specialization [48].

China’s antibiotic export trade network has extended to all corners of the globe, with a growing importance in developed markets like Europe and North America. The export markets for China’s antibiotic ingredients span various continents, with a strong focus on South Asia and Western Europe. The primary markets for antibiotic medicines (penicillins, streptomycins and their derivates) are developing regions such as East and West Africa, South America, and Southeast Asia. Exports to the US started to grow in and showed a sharp increase in , while exports to Japan surged in . As for antibiotic medicines (other antibiotics), their primary export destinations include Western Europe, North America, and South Asia. Exports to the US began to grow in , showed an accelerated increase in , and reached another peak in . This surge might be influenced by the overuse of antibiotics during the COVID-19 pandemic [51,52,53, 58]. It also reflects the impact of consistency evaluations for generic drugs [56] and other incentive policies aimed at boosting drug R&D [30, 66,67,68], which have improved drug quality, international recognition, and competitiveness, thereby driving exports [69]. The growing importance of the European and North American markets suggests a more rational and balanced global market distribution [23, 41].

China’s competitive advantage in antibiotics

China’s competitive advantage in antibiotic ingredients is likely to remain strong, whereas antibiotic medicines remain insufficiently competitive and are expected to continue to show a comparative disadvantage in the short term. The comparative advantage of antibiotic ingredients has shown a fluctuating upward trend, primarily due to costs associated with labor and the environment [70]. The comparative advantage of antibiotic medicines has been rising since around , likely due to incentives for R&D and changes in drug management policies.

From the relative index of comparative advantage, around , China’s comparative advantage in antibiotics began shifting towards antibiotic medicines, but in the short term, the export advantage of antibiotic ingredients will continue to dominate. The factors behind this transition likely include technological advancements like increased labor productivity, and enhanced innovation capacity. Policy support, resource endowment, economies of scale, and ingredient costs have also played significant roles [71]. This evolution suggests that China’s antibiotic export trade structure is being optimized, transitioning towards innovation, with industrial competitiveness strengthening and moving towards the higher end of the global industrial chain [72]. From the perspective of China’s domestic industry and industrial policy, it will be important to pursue consolidation and enhanced comparative advantage, strengthen independent innovation capacity, drive technological progress, and mitigate the adverse effects of declining labor supply, rising ingredient costs, and the appreciation of the effective exchange rate [71].

A curious finding noted above is that, as well as being among the top ten exporters of antibiotic ingredients (excluding Spain and Singapore), China is also one of the main export destinations. This is a surprising finding, and possibly indicates that China is importing comparatively higher quality antibiotic ingredients from these countries, or that multinational companies in China are purchasing ingredients from outside China (Fig. 3b). More research is needed to verify this.

Global antibiotic value chains

The COVID-19 pandemic has underscored China’s centrality in the supply of many health commodities [34], reviving discussions about reshaping global production networks. Overall, from a global perspective, COVID-19 has shown the importance of diversified and resilient supply and value chains in ensuring access to key medical technologies and commodities. As discussed above, countries like the US and India have implemented a series of incentives to boost domestic production of antibiotic ingredients [33, 73]. Reshaping the supply chain may not be achieved in the short term, but in the long run, it poses challenges for Chinese policymakers and industry [34, 50]. These include strengthening independent innovation and quality certification, boosting international competitiveness, and diversifying markets and export destinations [74, 75], supported by sound policies [34].

As we highlight above, access to antibiotics is a fundamental question for global health. The lack of adequate access is assessed to cause more deaths globally than antimicrobial resistance and furthers the emergence of resistance, predominantly in LMICs [76]. Faced with this, there is a need for greater support to initiatives and coordination to improve access to the right antibiotic at the right time. This is both a consideration for global health equity and for the sustainable management of antibiotics as a global good. It is also an important consideration in the negotiation of a pandemic treaty, given the importance of antibiotics in treating secondary bacterial infections in the case of a viral pandemic as well as in the management of possible bacterial threats [2]. China’s significance in global antibiotic value chains, its huge manufacturing capability (and linked cost advantages in the supply of many health commodities), as well as its rapid scientific and technological progress, inevitably make the country an important part of arrangements that are needed to ensure equitable global access to antibiotics in the future [1].

This study also has limitations. Although volume or unit value is not found to be a relevant measure in this study, analyzing only trade value may overlook the pricing of more specific types of antibiotics in different markets and how prices may be affecting trade [36]. Additionally, the unit value of antibiotics exported from China is relatively low compared to other major antibiotic-exporting countries in Europe and America. Consequently, China’s export share of antibiotics, calculated based on export value, may be underestimated compared to calculations based on export volume.

What Consumers Need to Know about the Use of Antibiotics in Food Animal Production

When reading the headlines of many press articles, you might get the impression that U.S. meat, poultry and dairy products are routinely contaminated with antibiotics. The truth is that many of these headlines are misleading. For example, the U.S. Food and Drug Administration recently conducted a study of antibiotic contamination in milk from dairy cows. The study targeted producers that had a past failed residue test in meat from their cull cows (cows no longer producing milk, so are sold for meat) in comparison to a group of producers without a history of a failed residue test. The result showed that 99.22 percent of the combined samples had no residues. However, after the FDA released the results, headlines contained misleading information implying that almost 1 percent of U.S. milk supplies were tainted with antibiotics. The problem is that the FDA targeted farms with a history of non-compliance, so it was not a random sample. In short, non-compliant farms were over-represented in the study (about 50 percent of the samples), meaning actual percentage of milk produced with residues is far lower than the study’s 0.78 percent rate. 

The goal here is to provide answers to common questions regarding the use of antibiotics in animal agriculture. The focus is on why antibiotics are used in meat animal production and the potential to contribute to antibiotic-resistant bacterial infections in humans.

1. Why do farmers use antibiotics in livestock production?
   First, antibiotics are used to prevent, treat and control bacterial infections in livestock. Just like humans, animals can contract infections, such as pneumonia. Antibiotics are used to humanely and economically treat and prevent these diseases. While often portrayed as cruel and uncaring by some in the media, the vast majority of livestock producers are very concerned about the welfare of animals under their care. Leaving sick animals to suffer from infections that are easily treated with antibiotics is cruel and inhumane. In addition to their humanity, farmers stay in business and feed their own families by earning profits through livestock and milk production. Unhealthy animals are unprofitable, can infect other animals in the herd and may die. In short, it is in farmers’ best interest to provide appropriate veterinary care for sick and injured animals.
   
   Secondly, antibiotics can increase animal performance. By using antibiotics, farmers can produce more meat with less feed input. Some antibiotics change the colony of bacteria in the rumen (one of four stomachs in cattle) to produce more of the compounds needed by cattle for growth. Some are used prophylactically to prevent diseases that are very difficult to control once the animal is infected. Importantly, the antibiotics used to increase production (a class of products referred to as “ionophores”) are not used to treat people, nor do they leave residues in meat if properly used. Antibiotics used to treat diseases in humans can no longer be used in livestock to improve production—they are strictly used for the prevention, control and treatment of disease.
2. Why has the use of some antibiotics in U.S. animal agriculture been discontinued or regulated?
   The pharmaceutical industry voluntarily agreed to eliminate non-therapeutic uses of some classes of antibiotics to reduce the likelihood that resistant bacteria develop and threaten human health. There are several classes of antibiotics that are used in both humans and livestock production. There is some probability that the continued use of these antibiotics to improve performance of livestock would have sped up resistance in bacteria that infect people. To our knowledge, there have been no documented cases of infections in people attributed to antibiotic-resistant bacteria originating from livestock. However, cases of individuals being colonized (the presence of bacteria without illness) by antibiotic-resistant bacterial strains have been documented. These strains are believed to have originated in livestock and the colonized individuals often have been in contact with livestock (Landers et al.). So, there are reasons to be concerned about the potential for impacting human health. Out of an abundance of precaution, classes of antibiotic drugs used in human medical care cannot be used in animals except for purposes of disease prevention, control and treatment.
   
   Sources:
   Lander, T.F., B. Cohen, T.E. Wittum, E.L. Larson. “A Review of Antibiotic Use in Food Animals: Perspective, Policy, and Potential,” Public Health Reports 127 (Jan-Feb ):4-22.
   
   
3. Why not eliminate all antibiotics in animal agriculture?
   There are three reasons not to eliminate antibiotics in animal agriculture. First, it would be inhumane to allow animals to suffer when they contract diseases that can be treated or prevented with antibiotics. Second, it is unclear what the public health benefits would be from eliminating usage for prevention, control and treatment of disease in animals. Further study is warranted, but it is likely that the animal welfare and economic impacts would far outweigh the limited benefits derived from a complete ban. Lastly, it is not economically feasible to allow animals to suffer and/or die from treatable and/or preventable diseases. The agricultural and food sector contributes about $1 trillion to the U.S. economy and provides about 11 million jobs, 21 percent of all jobs in the U.S. If antibiotics were totally eliminated, far fewer meat and milk animals would be produced in the U.S., making food far more expensive and eliminating many jobs. The poorest of U.S. citizens would suffer the most from increased food prices. Given the U.S. exported over 3.5 million metric tons of meat products worth over $12.3 billion in , foreign consumers would also be impacted, with the poor the most significantly harmed.
   
   Sources:
   

   U.S. Meat Export Federation

4. How do we know that meat, eggs and milk do not contain potentially dangerous antibiotic residue levels?
   When antibiotics are used to prevent, control or treat disease, livestock producers are required to stop using the antibiotic for a specified length of time (called a withdrawal period) before selling animals for processing. The withdrawal period assures residues in excess of allowable limits will not be present in carcasses, if the producer follows protocols.
   
   The USDA inspects animal carcasses to reduce the likelihood that meat is sold with antibiotic residues in excess of allowable limits. Producers selling animals that test positive for antibiotic residues face regulatory action, destruction of carcasses and increased testing of future animals sold for slaughter.
   
   Antibiotics used in animal agriculture are labeled with instructions limiting the amount of the product injected, fed or consumed through water and mandatory withdrawal period. They also include instructions on method of injection for injectable drugs. These instructions, if followed, greatly reduce the likelihood of a positive test for antibiotic residues.
   
   The USDA and Food and Drug Administration test for antibiotic residues in carcasses and food products. Carcasses testing positive for residues are condemned and are not used for human consumption. Despite all precautions, there are very isolated cases of meat with antibiotic residues reaching consumers. In a very small percentage of those cases, there were adverse effects, such as allergic reactions. A study (Doyle) reported two cases, one from and another from .
   Sources:
   USDA Residue Sampling Plans
   Doyle, M.E. “Veterinary Drug Residues in Processed Meats—Potential Health Risk: A Review of the Scientific Literature,” Food Research Institute Briefings, University of Wisconsin—Madison, March .
5. Are more antibiotics used in veterinary medicine than in human medicine?
   If we just look at the quantity used, then yes. However, there are far more farm animals, including beef and dairy cattle, sheep, goats and poultry, than humans in the U.S. According to an article in the Journal of the American Veterinary Medical Association, humans and their pets use at least ten times more antibiotics per year than is used for food-producing animals when adjusted for the weight of people and their pets versus the weight of animals used for food production (Barber). This suggests, according to Barber, that human and pet use of antibiotics is a more likely source of antibiotic resistance.
   
   Source:
   Barber, D.A. “New perspectives on transmission of foodborne pathogens and antimicrobial resistance,” Journal of the American Veterinary Medical Association 218, n. 10 (May ): -.

Cheryl S. DeVuyst
Professor

Are you interested in learning more about Jiayi Eprinomectin for Pets? Contact us today to secure an expert consultation!